← Back to Search

Stem Cell Transplantation

1 for Blood Cancers (HPDSC Trial)

N/A
Waitlist Available
Led By Lolie Yu, MD
Research Sponsored by Celgene Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* suitable UCB collected from partially or fully HLA matched related donor * subject requires umbilical cord transplantation
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or nonmalignant disorders potentially curable with stem cell transplantation and to assess potential restoration of normal hematopoiesis and immune function in subjects with these disorders

Eligible Conditions
  • Blood Cancers

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
all subjects will be treated with UCB and HPDSC

Find a Location

Who is running the clinical trial?

Celgene CorporationLead Sponsor
445 Previous Clinical Trials
58,640 Total Patients Enrolled
Lolie Yu, MDPrincipal InvestigatorLouisiana State University Children's Hospital
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top